A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Am J Kidney Dis
; 67(6): 861-71, 2016 Jun.
Article
en En
| MEDLINE
| ID: mdl-26827289
Palabras clave
Erythropoietin (EPO); chronic kidney disease (CKD); dialysis; dosing; erythropoiesis-stimulating agent (ESA); hemoglobin; hemoglobin response rate; hepcidin; hypoxia-inducible factor (HIF); pharmacodynamics; pharmacokinetics; phase II; prolyl hydroxylase inhibitor (PHI); randomized controlled trial (RCT); reticulocyte count
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Barbitúricos
/
Insuficiencia Renal Crónica
/
Prolina Dioxigenasas del Factor Inducible por Hipoxia
/
Inhibidores de Prolil-Hidroxilasa
/
Glicina
/
Anemia
Tipo de estudio:
Clinical_trials
/
Guideline
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Kidney Dis
Año:
2016
Tipo del documento:
Article